Post-Procedure Care Instructions for O-Shot (Platelet-Rich Plasma Vaginal Injection)
Based on current evidence, post-procedure care after O-shot should focus on avoiding NSAIDs for pain management, limiting sexual activity for 3-7 days, and monitoring for infection, though standardized protocols remain poorly defined in the literature.
Immediate Post-Procedure Period (First 24-48 Hours)
Pain Management
- Avoid NSAIDs (ibuprofen, naproxen) immediately after injection as these may theoretically interfere with platelet function and growth factor release 1, 2
- Use acetaminophen (Tylenol) for discomfort if needed
- Apply ice packs externally to the vulvar area for 10-15 minutes at a time to reduce swelling
- Mild discomfort, bruising, or swelling at injection sites is expected and typically resolves within 2-3 days
Activity Restrictions
- Abstain from sexual intercourse for 3-7 days to allow initial tissue integration 3, 4
- Avoid strenuous exercise or activities that increase pelvic pressure for 48 hours
- No tampons, douching, or insertion of anything into the vagina for at least 3 days
- Normal daily activities and walking are acceptable
Hygiene and Wound Care
- Keep the area clean and dry
- Gentle external washing with mild soap and water is permitted
- Pat dry rather than rubbing
- Wear loose, breathable cotton underwear
- No swimming pools, hot tubs, or baths for 48-72 hours (showers are acceptable)
Days 3-14: Early Recovery Phase
Resuming Activities
- Sexual activity may typically resume after 3-7 days if no bleeding or significant discomfort persists 3, 4
- Gradually return to normal exercise routine after first week
- Continue avoiding NSAIDs for the first 7-10 days if possible 2
Expected Changes
- Some patients report increased sensitivity or mild tingling as tissue regeneration begins
- Bruising should resolve within 7-10 days
- Initial improvements in symptoms may begin as early as 2-4 weeks, though optimal results typically appear at 8-12 weeks 4
Follow-Up and Monitoring
Warning Signs Requiring Immediate Contact
- Fever >100.4°F (38°C)
- Increasing pain, redness, or warmth at injection sites
- Purulent discharge or foul odor
- Heavy vaginal bleeding
- Signs of allergic reaction (though rare with autologous products) 1
Scheduled Follow-Up
- First follow-up at 4-6 weeks to assess initial response 4
- Many protocols involve 3-4 treatment sessions spaced 4-6 weeks apart for optimal results 4
- Document baseline and post-treatment sexual function using validated scales (FSFI, FGSIS) 4
Important Caveats and Considerations
Safety Profile
Autologous PRP preparations are generally clinically safe with minimal adverse events reported across multiple studies 1, 3. The most common side effects are mild and transient: injection site discomfort, bruising, and temporary swelling 3, 5.
Lack of Standardization
A critical limitation is that PRP preparations are poorly standardized with wide variation in content, purity, and biological properties 1. This means outcomes may vary depending on:
- Preparation method used by your provider
- Platelet concentration achieved
- Activation protocols employed
- Injection technique and anatomical sites targeted
Evidence Quality
Current evidence for O-shot efficacy comes primarily from small case series and uncontrolled trials 3, 4. While results appear promising for sexual dysfunction and vaginal atrophy, definitive conclusions about efficacy require larger randomized controlled trials 1, 3.
Realistic Expectations
- Not all patients respond equally to treatment
- Multiple sessions are typically needed for optimal results 4
- Effects are not permanent; maintenance treatments may be required
- Individual results vary based on underlying condition severity and patient factors
Special Populations
Patients on Anticoagulation
- Discuss with your provider before the procedure
- May have increased bruising risk but procedure is generally safe
Active Infections
- Any vaginal, urinary, or pelvic infection should be treated before PRP injection
- Postpone procedure if active infection present
Immunocompromised Patients
- While autologous products are generally safe, discuss individual risk-benefit ratio with provider 1
The key to successful outcomes is maintaining regular follow-up, adhering to activity restrictions during the critical first week, and having realistic expectations about the timeline for improvement 4.